Advice was requested from the Regional Medicines Optimisation Committee (RMOC) regarding the most appropriate and practical approach for the ophthalmology monitoring of patients who are receiving long term hydroxychloroquine therapy. RMOC South has produced draft advice on Hydroxychloroquine retinopathy monitoring on behalf of the RMOC system. This document addresses how to keep patients safe  from the risk of retinopathy during long term hydroxychloroquine therapy for inflammatory diseases.

A version 1.4 Hydroxychloroquine document was presented and discussed at the RMOC South September 2020 meeting. Following discussion and comments received from RMOC South members the document was further amended to produce the attached version 1.5 document.

This consultation is now closed. However, if you have any questions please contact